The use of lisdexamfetamine dimesylate for the treatment of ADHD
Abstract
ADHD is a common neurobehavioral disorder characterized by significant impairment in attention, hyperactivity and impulsivity. Symptoms begin in childhood and can persist into adulthood. Current data suggest that abnormal functioning of the prefrontal cortex, cortical and subcortical regions of the brain have roles in ADHD. All currently approved drugs used to treat ADHD enhance dopamine and norepinephrine signals in these regions. Lisdexamfetamine dimesylate (LDX) is a long-acting amphetamine prodrug indicated for the treatment of ADHD and has been shown to be effective in children, adolescents and adults. The prodrug properties of LDX make it a desirable treatment because of its long duration of effect, and low intrasubject and intersubject pharmacokinetic variability, and attenuated response on measures of abuse liability when compared with immediate-release amphetamine. However, LDX is still classified as a controlled substance. In this article, the pharmacokinetic parameters and efficacy and safety of LDX are reviewed.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The active moiety of LDX crosses the blood-brain barrier and increases noradrenergic and dopaminergic neurotransmission, thereby exerting its therapeutic effects.
“The active moiety crosses the blood-brain barrier and increases noradrenergic and dopaminergic neurotransmission thereby exerting its therapeutic effects.”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [17]
Following administration, conversion of LDX to d-amphetamine occurs in approximately 1.5 hours, with duration from 1.5 to 13 hours in children and 2 to 14 hours in adults.
“Following administration, conversion of LDX to d-amphetamine occurs in approximately 1.5 hours, with duration from 1.5 to 13 hours in children and 2 to 14 hours in adults.”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [17]
Cites
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765 · see citing works
Kessler, R. C., Adler, L. A., Barkley, R., Biederman, J., Conners, C. K., Faraone, S. V., Greenhill, L. L., Jaeger, S., Secnik, K., Spencer, T., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.001 · Cited by 663 · see citing works
Swanson, J. M., Kinsbourne, M., Nigg, J., Lanphear, B., Stefanatos, G. A., Volkow, N., Taylor, E., Casey, B. J., Castellanos, F. X., & Wadhwa, P. D. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9019-9 · Cited by 580 · see citing works
Catecholamine Influences on Dorsolateral Prefrontal Cortical Networks
Arnsten, A. F. T. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.01.027 · Cited by 493 · see citing works
Kessler, R. C., Green, J. G., Adler, L. A., Barkley, R. A., Chatterji, S., Faraone, S. V., Finkelman, M., Greenhill, L. L., Gruber, M. J., Jewell, M., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.146 · Cited by 317 · see citing works
Adler, L. A., Goodman, D. W., Kollins, S. H., Weisler, R. H., Krishnan, S., Zhang, Y., & Biederman, J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0903 · Cited by 218 · see citing works
Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
Pennick (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s9749 · Cited by 170 · see citing works
Mosholder, A. D., Gelperin, K., Hammad, T. A., Phelan, K., & Johann-Liang, R. (2009) · Pediatrics · doi:10.1542/peds.2008-0185 · Cited by 155 · see citing works
Jasinski, D., & Krishnan, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109103113 · Cited by 149 · see citing works
Jain, R., Segal, S., Kollins, S. H., & Khayrallah, M. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.11.005 · Cited by 142 · see citing works
Wigal, T., Brams, M., Gasior, M., Gao, J., Squires, L., Giblin, J., & 316 Study Group (2010) · Behavioral and Brain Functions · doi:10.1186/1744-9081-6-34 · Cited by 136 · see citing works
Surman, C. B. H., Biederman, J., Spencer, T., Yorks, D., Miller, C. A., Petty, C. R., & Faraone, S. V. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10081172 · Cited by 135 · see citing works
McCarthy, S., Cranswick, N., Potts, L., Taylor, E., & Wong, I. C. K. (2009) · Drug Safety · doi:10.2165/11317630-000000000-00000 · Cited by 128 · see citing works
Winterstein, A. G., Gerhard, T., Shuster, J., Johnson, M., Zito, J. M., & Saidi, A. (2007) · Pediatrics · doi:10.1542/peds.2007-0675 · Cited by 119 · see citing works
the 311 Study Group, Wigal, S. B., Kollins, S. H., Childress, A. C., & Squires, L. (2009) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-3-17 · Cited by 112 · see citing works
Self-citationWeisler, R., Young, J., Mattingly, G., Gao, J., Squires, L., Adler, L., & 304 Study Group (2009) · CNS Spectrums · doi:10.1017/s1092852900024056 · Cited by 94 · see citing works
Ermer, J. C., Dennis, K., Haffey, M. B., Doll, W. J., Sandefer, E. P., Buckwalter, M., Page, R. C., Diehl, B., & Martin, P. T. (2011) · Clinical Drug Investigation · doi:10.2165/11588190-000000000-00000 · Cited by 35 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
Najib, J., Wimer, D., Zeng, J., Lam, K. W., Romanyak, N., Paige Morgan, E., & Thadavila, A. (2017) · Journal of Central Nervous System Disease · doi:10.1177/1179573517728090 · Cited by 17 · see citing works
- Authors
- Childress, A. C., & Sallee, F. R.
- Affiliations
- Center for Psychiatry and Behavioral Medicine (US)
- University of Cincinnati (US)
- ORCID
- Childress, Ann C
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2012-01
- Volume
- 12
- Issue
- 1
- Pages
- 13-26
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2152244724
- Cited by
- 18
- References
- 17
- Citations by year
- 2025: 1 · 2024: 1 · 2021: 1 · 2018: 1 · 2017: 2 · 2016: 5 · 2015: 2 · 2014: 3 · 2013: 2
- FWCI
- 0.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Neurotherapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Health Canada
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- lisdexamfetamine dimesylate, attention deficit hyperactivity disorder, dopamine, norepinephrine, prefrontal cortex, pharmacokinetics, abuse liability, treatment efficacy and safety, children and adults
- MeSH terms
- Lisdexamfetamine Dimesylate, Adolescent, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Clinical Trials as Topic, Dextroamphetamine, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
